Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 – For Medical Students & Physicians A complete 20-lesson, 300-page Chinese HSK 1 course with a companion app in 21 languages — free forever. Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Hepatitis C

Free Subscription Articles published in J Gastroenterol Retrieve available abstracts of 16 articles: HTML format

Single Articles

April 2026
1. TOYODA H, Atsukawa M
   Did the COVID-19 pandemic disrupt the continuity of post-SVR surveillance in HCV-cured patients?
   J Gastroenterol. 2026 Apr 25. doi: 10.1007/s00535-026-02426.
   PubMed    
   
   
   
2. HUO TI, Ho SY
   Evaluating liver reserve in direct-acting antiviral-treated hepatitis C patients: do we have better surrogate markers?
   J Gastroenterol. 2026 Apr 21. doi: 10.1007/s00535-026-02420.
   PubMed    
   
   
   January 2026
3. OHARA M, Kozuka R, Uchida Y, Iino C, et al
   Continuity of long-term follow-up in patients with chronic hepatitis C after sustained virologic response following direct-acting antiviral therapy: a nationwide real-world multicenter cohort study in Japan.
   J Gastroenterol. 2026 Jan 27. doi: 10.1007/s00535-026-02345.
   PubMed     Abstract available
   
   
   October 2025
4. TAHATA Y, Hikita H, Takaki A, Kurosaki M, et al
   Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial.
   J Gastroenterol. 2025 Oct 30. doi: 10.1007/s00535-025-02312.
   PubMed     Abstract available
   
   
   July 2025
5. YAMASAKI S, Nakahara T, Tsuge M, Yamaoka K, et al
   Metabolic dysfunction-associated steatotic liver disease affects the development of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients.
   J Gastroenterol. 2025 Jul 7. doi: 10.1007/s00535-025-02270.
   PubMed     Abstract available
   
   
   
6. SUZUKI T, Matsuura K, Tahata Y, Hikita H, et al
   Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy.
   J Gastroenterol. 2025 Jul 1. doi: 10.1007/s00535-025-02282.
   PubMed     Abstract available
   
   
   June 2025
7. KAWAGISHI N, Suda G, Tahata Y, Hikita H, et al
   Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosis.
   J Gastroenterol. 2025 Jun 20. doi: 10.1007/s00535-025-02275.
   PubMed     Abstract available
   
   
   February 2025
8. WATANABE T, Tokumoto Y, Ochi H, Mashiba T, et al
   Clinical factors to predict changes of esophagogastric varices after sustained viral response with direct-acting antiviral therapy.
   J Gastroenterol. 2025;60:222-234.
   PubMed     Abstract available
   
   
   November 2024
9. IWAMOTO T, Nozaki Y, Inoue T, Suda T, et al
   Histological improvement of fibrosis in patients with hepatitis C who achieved a 5-year sustained virological response to treatment with direct-acting antivirals.
   J Gastroenterol. 2024 Nov 25. doi: 10.1007/s00535-024-02165.
   PubMed     Abstract available
   
   
   September 2024
10. YAMAUCHI K, Maekawa S, Osawa L, Komiyama Y, et al
    Single-molecule sequencing of the whole HCV genome revealed envelope deletions in decompensated cirrhosis associated with NS2 and NS5A mutations.
    J Gastroenterol. 2024 Sep 3. doi: 10.1007/s00535-024-02146.
    PubMed     Abstract available
    
    
    May 2024
11. SUZUKI T, Matsuura K, Nagura Y, Ito K, et al
    MicroRNA-223-3p levels in serum-derived extracellular vesicles predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents.
    J Gastroenterol. 2024 May 13. doi: 10.1007/s00535-024-02115.
    PubMed     Abstract available
    
    
    
12. ATSUKAWA M, Tsubota A, Kondo C, Toyoda H, et al
    ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.
    J Gastroenterol. 2024 May 10. doi: 10.1007/s00535-024-02109.
    PubMed     Abstract available
    
    
    April 2024
13. LIU CH, Chang YP, Fang YJ, Cheng PN, et al
    Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals.
    J Gastroenterol. 2024 Apr 13. doi: 10.1007/s00535-024-02101.
    PubMed     Abstract available
    
    
    December 2023
14. UOJIMA H, Nakabayashi K, Yamasaki K, Sugiyama M, et al
    New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease.
    J Gastroenterol. 2023;58:1252-1260.
    PubMed     Abstract available
    
    
    October 2023
15. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
    J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02039.
    PubMed     Abstract available
    
    
    March 2023
16. SHIMAKAMI T, Setoyama H, Oza N, Itakura J, et al
    Development of performance indicators for hepatitis countermeasures as a tool for the assessment and promotion of liver cancer prevention in Japan.
    J Gastroenterol. 2023;58:257-267.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum